Table 3 Trajectory analysis outcomes showing factors associated with class membership of health-related quality of life during radium-223 therapy.
Class 1 Deteriorated (N = 50) | Class 2 Stable low (N = 9) OR (95% CI) | Class 3 Stable intermediate (N = 10) OR (95% CI) | Class 4 Stable high (N = 27) OR (95% CI) | Class 5 Improved (N = 8) OR (95% CI) | Class 6 Fluctuating (N = 9) OR (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Age | Reference | 1.00 | (0.92–1.09) | 1.04 | (0.96–1.13) | 0.99 | (0.94–1.05) | 1.01 | (0.93–1.10) | 1.04 | (0.96–1.14) |
Partnership | 0.66 | (0.07–6.00) | NE | - | 0.91 | (0.25–3.36) | 1.75 | (0.30–10.27) | NE | - | |
Opioid use | 9.00 | (1.66–48.70)* | 3.86 | (0.94–15.76) | 0.10 | (0.01–0.80)* | 3.21 | (0.75–13.74) | 0.74 | (0.14–3.98) | |
Hemoglobin | 1.34 | (0.50–3.55) | 1.22 | (0.48–3.05) | 2.29 | (1.14–4.62)* | 1.90 | (0.68–5.29) | 0.91 | (0.36–2.31) | |
Alkaline phosphatase (log) | 0.51 | (0.04–7.54) | 0.15 | (0.01–2.83) | 0.12 | (0.02–0.90)* | 3.72 | (0.41–34.12) | 0.12 | (0.01–2.79) | |
Prostate-specific antigen (log) | 0.90 | (0.34–2.42) | 0.55 | (0.22–1.35) | 1.29 | (0.62–2.30) | 3.05 | (0.98–9.53) | 1.11 | (0.41–3.04) | |
Number of prior therapies | 1.03 | (0.51–2.08) | 1.17 | (0.60–2.26) | 1.27 | (0.80–2.00) | 2.17 | (1.12–4.22)* | 0.92 | (0.44–1.89) | |
ECOG performance status | |||||||||||
ECOG 1 | 2.89 | (0.48–17.49) | 10.11 | (1.14–89.43)* | 0.90 | (0.34–2.44) | 7.22 | (0.78–67.14) | 1.93 | (0.38–9.67) | |
ECOG 2-3 | 6.50 | (0.88–47.90) | 8.67 | (0.67–112.04) | 0.27 | (0.03–2.46) | 13.00 | (1.14–147.82)* | 1.93 | (0.38–9.67) | |
